Literature DB >> 7970948

Antimicrobial susceptibility of nasopharyngeal isolates of potential pathogens recovered from infants before antibiotic therapy: implications for the management of otitis media.

H Faden1, G Doern, J Wolf, M Blocker.   

Abstract

Antimicrobial susceptibility was determined for strains of Streptococcus pneumoniae, nontypable Haemophilus influenzae and Moraxella catarrhalis recovered from the nasopharynxes of children followed from birth. The bacteria tested were the first potential pathogens isolated from each child before any treatment with antibiotics. Minimal inhibitory concentrations of commonly used oral antibiotics demonstrated the following overall rates of resistance for (1) S. pneumoniae: penicillin 1.2% (intermediate susceptibility 4.8%), trimethoprim-sulfamethoxazole 20%; (2) nontypable H. influenzae: ampicillin 32%, cefaclor 17%; (3) M. catarrhalis: ampicillin 90%, trimethoprim-sulfamethoxazole 19%. Antibiotic regimens used for treatment of otitis media may have to be evaluated in light of changing antibiotic susceptibilities.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970948     DOI: 10.1097/00006454-199407000-00005

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  2 in total

Review 1.  Diagnosis and treatment of acute and subacute sinusitis in children and adults.

Authors:  G A Incaudo; L G Wooding
Journal:  Clin Rev Allergy Immunol       Date:  1998 Spring-Summer       Impact factor: 10.817

2.  An application of outer membrane protein p6-specific enzyme-linked immunosorbent assay for detection of haemophilus influenzae in middle ear fluids and nasopharyngeal secretions.

Authors:  Muneki Hotomi; Akihisa Togawa; Masamitsu Kono; Gen Sugita; Rinya Sugita; Yutaka Fujimaki; Yosuke Kamide; Akihiro Uchizono; Keiko Kanesada; Shoichi Sawada; Naohiro Okitsu; Hisayo Masuda; Hideaki Tanaka; Yumi Tanaka; Noboru Yamanaka
Journal:  PLoS One       Date:  2013-08-28       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.